A progesterone prescription can involve more than one conversation: the clinician explains why it is proposed, while the pharmacy identifies the product it will supply. MyMenopauseRx publishes details about preferred pharmacies, transfers and generic changes that make this division particularly relevant. Those details are useful, but they cannot replace the label for the actual capsule.
Reviewed September 29, 2026, this assessment considers the service’s treatment menu and telehealth FAQ. It confirms a relevant progesterone-prescribing service, not a particular dispensing result. No visit, transfer, refill, insurance claim or package was tested.
In this article
The treatment list names the hormone without assigning one form
MyMenopauseRx’s treatments page says it prescribes FDA-approved estradiol and progesterone and lists several dosage forms across its hormone options, including capsules. The FAQ repeats the progesterone prescribing statement. This supports the service’s relevance, but the combined list should not be read as every hormone being available in every named form.
Ask which preparation and route the clinician is actually proposing. No exact manufacturer or capsule label was established in these pages. Gennev’s review considers a broader hormonal-treatment category with less product detail. A review can recognize differing specificity without converting either service’s description into a guarantee of a particular prescription.
The purpose of progesterone should be visible in the care plan
The telehealth FAQ says the care plan is attached to the visit in the patient dashboard. That is a practical place to seek a clear explanation of each proposed medicine. The explanation should distinguish the reason for progesterone from the reason for estrogen or any other treatment being considered.
Our medicine-purpose guide helps organize those questions. FDA menopause information addresses hormone benefits, risks and the uterine-lining issue in relevant estrogen treatment. It does not determine an individual plan or make broad symptom advertising proof of a particular medicine’s effect. A written recommendation is most useful when the patient can understand its purpose and the professional responsible for follow-up.
A preferred pharmacy is a destination, not an ingredient guarantee
MyMenopauseRx’s FAQ lets patients specify a preferred local or mail-order pharmacy. After an order has been sent, it describes a pharmacy-to-pharmacy transfer; resending through the service may involve a separate Change Pharmacy message visit. These are distinct processes, with possible questions about timing and charges.
Choosing a destination does not itself select the capsule manufacturer or settle what is in stock. Ask the dispensing team what preparation matches the order and where its ingredient information can be found. The capsule-excipient guide keeps that inquiry tied to the actual product. No transfer or message-visit price was established by the public FAQ reviewed here.
A generic change should not disappear behind the shared hormone name
The FAQ discusses changes in a generic manufacturer and directs people experiencing unwanted effects to the pharmacy. The practical value of that passage is that it recognizes a change in the supplied product as something worth discussing. It should not be converted into this review’s assurance that any particular change is inconsequential for an individual.
For example, the Prometrium label specifies peanut oil and gelatin, but that does not identify every generic capsule or establish what this service supplies. A pharmacist can review the actual replacement label alongside a stated ingredient concern. Keep the clinical team involved in questions about symptoms or treatment; the review does not recommend substituting, stopping or adjusting a medicine.
The visit description is more precise than a headline duration
The service FAQ describes about thirty minutes of professional work around a video visit, including twenty minutes face to face and additional review and documentation. It also says the service complements local care rather than replacing a primary clinician for needs requiring a physical examination. Those qualifications help set realistic expectations for a capsule discussion.
A question about swallowing, ingredients or an unwanted effect may need both dispensing information and clinical assessment. Our drowsiness guide, together with MedlinePlus, identifies why alertness concerns deserve professional attention. The availability of a video appointment does not show that every concern can be resolved remotely or through a brief message.
Insurance exclusions and cancellation charges remain material
The FAQ says the service does not accept Medicare, Medicaid or HMO plans. For accepted insurance, an unmet deductible can leave the patient responsible for an amount that exceeds a self-pay rate. Medicine coverage is handled through the pharmacy, and no exact capsule price was established by these records.
The same FAQ requires cancellation at least twenty-four hours ahead to avoid a non-refundable $99 charge and lists a $99 missed-appointment fee. A disrupted partial visit is rescheduled rather than refunded. These terms should accompany any impression that using insurance makes the entire arrangement predictable. Pandia’s review examines a different separation between care-plan payments and pharmacy costs.
Refills create another opportunity to check the record
MyMenopauseRx’s published process links a refill request to a visit and asks patients unsure of the appropriate appointment to contact the care coordinator. That is a service procedure, not a personal prescription schedule. The remaining question is how the actual patient’s medicine, pharmacy information and follow-up needs will be reviewed at that encounter.
The follow-up guide distinguishes a renewal decision from dispensing logistics. Keep questions specific to the current preparation rather than assume that a previous package identifies all later supplies. The public record supports progesterone-related clinical care and several useful pharmacy procedures; it does not verify individual suitability, the exact capsule or the result of using it.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- MyMenopauseRx: treatmentsProvider catalog naming progesterone and collective dosage forms; no inference that every hormone comes in every listed form · Checked 2026-09-29
- MyMenopauseRx: telehealth FAQDated provider visit/pharmacy/refill/coverage/cancellation record; personal prescription, generic identity and clinical decisions remain unverified · Checked 2026-09-28
- FDA: MenopauseCurrent federal patient guidance; product-dependent benefits/risks and prevention limits, no personal eligibility or class-wide label-change inference · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsulesExact Acertis product labeling updated July23,2026; oral micronized progesterone, peanut oil/gelatin and peanut-allergy restriction, not a label for every provider or generic · Checked 2026-09-29
- MedlinePlus: ProgesteroneFederal medication information; oral-capsule identity, possible dizziness/drowsiness and professional discussion only; public schedules not reproduced as reader instructions · Checked 2026-09-29